Scientists at the University of Virginia School of Medicine and the University of Michigan have developed a monoclonal antibody to stop sepsis, a deadly full-body infection, SİA informs via EurekAlert.
The antibody also has the potential to treat a broad array of other inflammatory conditions, including autoimmune disorders, their research indicates.
In initial testing in lab mice, the antibody proved versatile and showed “transformative potential for combating life-threatening inflammatory diseases,” the researchers report in a new scientific paper. Potential applications could include deadly acute respiratory distress syndrome (ARDS), which rose to public attention during the COVID-19 pandemic, as well as ischemia-reperfusion injury, which is tissue damage caused when blood flow is cut off and restored. (Ischemia-reperfusion injury is a major problem for organ transplantation.)
The researchers say their work has also shed light on the molecular causes of sepsis and has the potential to produce an important tool for diagnosing the condition and monitoring patients.
“This is the kind of breakthrough that can change the standard of care,” said Jianjie Ma, PhD, of UVA’s Department of Surgery and UVA Cancer Center. “By combining complementary expertise in basic science, innovation and translational medicine, and by working closely with our industry partners, we’ve developed a first-in-class antibody with the potential to save countless lives from sepsis and other severe inflammatory diseases.”
Further, early testing suggests the antibody can do so without the unwanted side effects of existing sepsis treatments, such as unintended suppression of the immune system. In the initial studies, the antibody was able to stop inflammatory cytokines and restore the function of immune cells called macrophages, all while protecting against sepsis-induced lung injury, the scientists report in their new paper.
In addition to the antibody’s potential therapeutic applications, the scientists say the tools they are using to produce it may be useful for detecting and monitoring sepsis. Their platform, called PEdELISA, can quantify six cytokines from a single drop of plasma within two hours.
Bütün xəbərlər Facebook səhifəmizdə
.jpg)
.jpg)
.jpg)
USD
EUR
GBP
RUB